Zolfaghari Emameh Reza, Falak Reza, Bahreini Elham
Department of Energy and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), 14965/161, Tehran, Iran.
Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Biol Proced Online. 2020 Jun 19;22:11. doi: 10.1186/s12575-020-00124-6. eCollection 2020.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears with common symptoms including fever, dry cough, and fatigue, as well as some less common sysmptoms such as loss of taste and smell, diarrhea, skin rashes and discoloration of fingers. COVID-19 patients may also suffer from serious symptoms including shortness of breathing, chest pressure and pain, as well as loss of daily routine habits, pointing out to a sever reduction in the quality of life. COVID-19 has afftected almost all countries, however, the United States contains the highest number of infection (> 1,595,000 cases) and deaths cases (> 95,000 deaths) in the world until May 21, 2020. Finding an influential treatment strategy against COVID-19 can be facilitated through better understanding of the virus pathogenesis and consequently interrupting the biochemical pathways that the virus may play role in human body as the current reservoir of the virus.
In this study, we combined system biology and bioinformatic approaches to define the role of coexpression of angiotensin-converting enzyme 2 (ACE2), neprilysin or membrane metallo-endopeptidase (MME), and carbonic anhydrases (CAs) and their association in the pathogenesis of SARS-CoV-2. The results revealed that ACE2 as the cellular attachment site of SARS-CoV-2, neprilysin, and CAs have a great contribution together in the renin angiotensin system (RAS) and consequently in pathogenesis of SARS-CoV-2 in the vital organs such as respiratory, renal, and blood circulation systems. Any disorder in neprilysin, ACE2, and CAs can lead to increase of CO concentration in blood and respiratory acidosis, induction of pulmonary edema and heart and renal failures.
Due to the presence of ACE2-Neprilysin-CA complex in most of vital organs and as a receptor of COVID-19, it is expected that most organs are affected by SARS-CoV-2 such as inflammation and fibrosis of lungs, which may conversely affect their vital functions, temporary or permanently, sometimes leading to death. Therefore, ACE2-Neprilysin-CA complex could be the key factor of pathogenesis of SARS-CoV-2 and may provide us useful information to find better provocative and therapeutic strategies against COVID-19.
2019冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,常见症状包括发热、干咳和乏力,还有一些不太常见的症状,如味觉和嗅觉丧失、腹泻、皮疹以及手指变色。COVID-19患者还可能出现严重症状,包括呼吸急促、胸痛和胸闷,以及日常生活习惯丧失,这表明生活质量严重下降。COVID-19几乎影响了所有国家,然而,截至2020年5月21日,美国的感染病例数(>159.5万例)和死亡病例数(>9.5万例)位居世界之首。通过更好地了解病毒发病机制,进而阻断病毒在作为当前病毒宿主的人体中可能发挥作用的生化途径,有助于找到有效的COVID-19治疗策略。
在本研究中,我们结合系统生物学和生物信息学方法来确定血管紧张素转换酶2(ACE2)、中性肽链内切酶或膜金属内肽酶(MME)以及碳酸酐酶(CAs)共表达的作用及其在SARS-CoV-2发病机制中的关联。结果显示,ACE2作为SARS-CoV-2的细胞附着位点,中性肽链内切酶和碳酸酐酶在肾素血管紧张素系统(RAS)中共同发挥着重要作用,进而在呼吸、肾脏和血液循环系统等重要器官的SARS-CoV-2发病机制中起作用。中性肽链内切酶、ACE2和碳酸酐酶的任何紊乱都可能导致血液中二氧化碳浓度升高和呼吸性酸中毒,引发肺水肿以及心脏和肾衰竭。
由于ACE2-中性肽链内切酶-碳酸酐酶复合物存在于大多数重要器官中且作为COVID-19的受体,预计大多数器官会受到SARS-CoV-2的影响,如肺部炎症和纤维化,这可能反过来暂时或永久地影响其重要功能,有时甚至导致死亡。因此,ACE-D中性肽链内切酶-碳酸酐酶复合物可能是SARS-CoV-2发病机制的关键因素,可能为我们寻找更好的针对COVID-19的激发和治疗策略提供有用信息。